Shares of Monte Rosa Therapeutics (GLUE) have gained 16.4% over the past four weeks to close the last trading session at $10.36, but there could still be a solid upside left in the stock if short-term ...
Shares of CRISPR Therapeutics AG (CRSP) have gained 0.8% over the past four weeks to close the last trading session at $51.17, but there could still be a solid upside left in the stock if short-term ...
The mean of analysts' price targets for MBIA (MBI) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in ...
The consensus price target hints at a 25.2% upside potential for Five9 (FIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...